Cargando…

Status migrainosus inpatient treatment with eptinezumab (SMITE): study protocol for a randomised controlled trial

INTRODUCTION: Status migrainosus is a disabling complication of migraine, which frequently results in hospitalisation. For patients who fail to respond to simple analgesia, triptans and intravenous prochlorperazine or chlorpromazine, there are limited treatment options, and a paucity of high-quality...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ray, Jason Charles, Chen, Zhibin, Ramsay, Georgia, Germaine, Jack, Hutton, Elspeth J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905943/ https://www.ncbi.nlm.nih.gov/pubmed/35260463 http://dx.doi.org/10.1136/bmjopen-2021-059647

Ejemplares similares

Short Term Oral Methylergonovine Maleate Prophylaxis for Status Migrainosus. Case Series and Review of Literature
por: Haque, Najiya, et al.
Publicado: (2019)

Role of intravenous levetiracetam in status migrainosus
por: Farooq, Muhammad U., et al.
Publicado: (2007)

Tozinameran: Status migrainosus: case report
Publicado: (2022)

Status migrainosus as an initial presentation of multiple sclerosis
por: Alroughani, Raed, et al.
Publicado: (2015)

Fatal status migrainosus in Chiari 1 malformation
por: Jokonya, Luxwell, et al.
Publicado: (2019)

CADASIL presenting as status migrainosus and persisting aura without infarction
por: Sacco, Simona, et al.
Publicado: (2008)

Dihydroergotamine Complicating Reversible Cerebral Vasoconstriction Syndrome in Status Migrainosus
por: Mullaguri, Naresh, et al.
Publicado: (2018)

Status Migrainosus and Endometriosis: A Case Report and Review of the Literature
por: Frankel, Lexi R, et al.
Publicado: (2021)

Persistent aura and status migrainosus in CADASIL syndrome: A case report
por: Hamid, Mohamed, et al.
Publicado: (2022)

Eptinezumab for migraine
Publicado: (2022)

SMITE: an R/Bioconductor package that identifies network modules by integrating genomic and epigenomic information
por: Wijetunga, N. Ari, et al.
Publicado: (2017)

Adding eptinezumab to brief patient education to treat chronic migraine and medication-overuse headache: Protocol for RESOLUTION—A phase 4, multinational, randomized, double-blind, placebo-controlled study
por: Jensen, Rigmor H., et al.
Publicado: (2023)

SMITE: A toolbox for creating Psychophysics Toolbox and PsychoPy experiments with SMI eye trackers
por: Niehorster, Diederick C., et al.
Publicado: (2019)

Intravenous Lidocaine and Ketamine Infusions for Headache Disorders: A Retrospective Cohort Study
por: Ray, Jason C., et al.
Publicado: (2022)

A Review of Eptinezumab Use in Migraine
por: Datta, Abhigyan, et al.
Publicado: (2021)

Autonomic symptoms in migraine: Results of a prospective longitudinal study
por: Ray, Jason C., et al.
Publicado: (2022)

Risk and Predisposing Factors for Suicide Attempts in Patients with Migraine and Status Migrainosus: A Nationwide Population-Based Study
por: Harnod, Tomor, et al.
Publicado: (2018)

Brachial Artery Vasospasm From Sequential Use of Intravenous Promethazine and Dihydroergotamine for Treatment of Status Migrainosus: A Case Report
por: Johns, Christopher, et al.
Publicado: (2023)

Eptinezumab for migraine prevention in patients 50 years or older
por: Martin, Vincent, et al.
Publicado: (2022)

Managing Migraine: Medication Overuse Headache and Treatment with Eptinezumab
por: Limberg, Nicole
Publicado: (2023)

Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2
por: Lipton, Richard B., et al.
Publicado: (2020)

Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients
por: Baker, Brian, et al.
Publicado: (2021)

Progress in the Treatment of Migraine Attacks: From Traditional Approaches to Eptinezumab
por: Scuteri, Damiana, et al.
Publicado: (2021)

Pre-stroke socioeconomic status predicts upper limb motor recovery after inpatient neurorehabilitation
por: Wolf, S., et al.
Publicado: (2022)

Cerebral Large Vessel Occlusion Caused by Fat Embolism—A Case Series and Review of the Literature
por: Ooi, Suyi, et al.
Publicado: (2021)

The eptinezumab:CGRP complex structure – the role of conformational changes in binding stabilization
por: David, Laurent, et al.
Publicado: (2021)

Study protocol for a phase II randomised, double-blind, placebo-controlled trial of perampanel as an antiepileptogenic treatment following acute stroke
por: Nicolo, John-Paul, et al.
Publicado: (2021)

Status migrainosus: a potential adverse reaction to Comirnaty (BNT162b2, BioNtech/Pfizer) COVID-19 vaccine—a case report
por: Consoli, Stefano, et al.
Publicado: (2021)

Simultaneous Multiple Interaction T-cell Engaging (SMITE) Bispecific Antibodies Overcome Bispecific T-cell Engager (BiTE) Resistance Via CD28 Co-Stimulation
por: Correnti, Colin E., et al.
Publicado: (2018)

Population pharmacokinetic and exposure‐response analysis of eptinezumab in the treatment of episodic and chronic migraine
por: Baker, Brian, et al.
Publicado: (2020)

Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine
por: McAllister, Peter, et al.
Publicado: (2022)

Pharmacokinetics and Safety of Eptinezumab in Healthy Chinese Participants: A Randomized Clinical Trial
por: Li, Xue-Ning, et al.
Publicado: (2023)

Levetiracetam vs. Fosphenytoin for Second-Line Treatment of Status Epilepticus: Propensity Score Matching Analysis Using a Nationwide Inpatient Database
por: Nakamura, Kensuke, et al.
Publicado: (2020)

Efficacy of ketamine in refractory convulsive status epilepticus in children: a protocol for a sequential design, multicentre, randomised, controlled, open-label, non-profit trial (KETASER01)
por: Rosati, Anna, et al.
Publicado: (2016)

Imaging in headache disorders
por: Ray, Jason C, et al.
Publicado: (2022)

Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials
por: Smith, Timothy R., et al.
Publicado: (2021)

Eptinezumab: A calcitonin gene-related peptide monoclonal antibody infusion for migraine prevention
por: Morgan, Kelsey Woods, et al.
Publicado: (2021)

Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine
por: Buse, Dawn C., et al.
Publicado: (2022)

Effectiveness and Safety of Eptinezumab in Episodic and Chronic Migraine Headache in the UAE: A Retrospective Study
por: Bader, Yazan, et al.
Publicado: (2023)

Eptinezumab for the Prevention of Migraine: Clinical Utility, Patient Preferences and Selection – A Narrative Review
por: Altamura, Claudia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_97j4om8dfpms6hf6m820v4j7aa